Page last updated: 2024-11-05

troglitazone and Adenocarcinoma of Lung

troglitazone has been researched along with Adenocarcinoma of Lung in 1 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Adenocarcinoma of Lung: A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Tsujiya, Y1
Hasegawa, A1
Yamamori, M1
Okamura, N1

Other Studies

1 other study available for troglitazone and Adenocarcinoma of Lung

ArticleYear
Troglitazone-Induced Autophagic Cytotoxicity in Lung Adenocarcinoma Cell Lines.
    Biological & pharmaceutical bulletin, 2022, Volume: 45, Issue:3

    Topics: Adenocarcinoma of Lung; Apoptosis; Autophagy; Cell Line; Cell Line, Tumor; Cell Proliferation; Chrom

2022